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Abstract
Objectives Since the introduction of the German health
care reform in January 2011, an early benefit assessment
(EBA) is required for all new medicines. Pharmaceutical
manufacturers have to submit a benefit dossier for evalu-
ation by the Institute for Quality and Efficiency in Health
Care (IQWiG). A final decision is made by the Federal
Joint Committee (G-BA). The aim of this investigation was
to analyse the outcomes 18 months after introduction of the
new legislation and to identify critical areas requiring
further discussion and development.
Methods All EBAs commenced prior to June 2012 were
included. The G-BA website was used to obtain manu-
facturers’ benefit dossiers, IQWiG assessments, and G-BA
decisions. Four areas of interest were analysed: levels of
additional benefit, appropriate comparative therapy (ACT),
patient-relevant endpoints, and adverse events.
Results Twenty-seven EBAs were analysed. IQWiG sta-
ted a benefit in 50 % of EBAs, whereas G-BA stated a
benefit in 63 %, but only in 50 % of identified subgroups
and 40 % of patients involved. In 12 EBAs, the ACT sug-
gested by G-BA differed from the comparator used in phase
III trials. The G-BA reported no benefits on health-related
quality of life. Discrepancies arose in morbidity outcomes
such as ‘progression-free survival’ and ‘sustained virolog-
ical response’. Categorisation and balancing of adverse
events was conducted within various assessments.
Conclusions Considerable variance was observed in the
levels of additional benefit reported by pharmaceutical
manufacturers, IQWiG and G-BA. The areas of disagree-
ment included ACT selection, definition of subgroups and
patient-relevant endpoints, and classification and balancing
of adverse events.
Keywords Health care reform  (Early) benefit
assessment  Appropriate comparative therapy 
Market access  AMNOG
JEL Classifiaction I10  I11  I18
Introduction
The new Act to Reorganize the Pharmaceuticals Market in
the Statutory Health Insurance (SHI) System [Gesetz zur
Neuordnung des Arzneimittelmarktes in der gesetzlichen
Krankenversicherung (AMNOG)] [1], which was intro-
duced by the German Parliament based on an initiative of
the Ministry of Health, passed through Federal Parliament
on 11 November 2010 and came into effect on 1 January
2011. A key component of AMNOG is the introduction of a
mandatory benefit assessment, with the subsequent price
negotiation process for new medicines to be completed
within 1 year of product launch (Fig. 1) [1]. Pharmaceutical
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manufacturers have to submit a benefit dossier to the Fed-
eral Joint Committee (Gemeinsamer Bundesausschuss,
G-BA), the key legal institution of the self-administration
within the German health care system, before the medicine
is made commercially available in Germany. The G-BA is
the highest decision-making body of the joint self-govern-
ing board of stakeholders in healthcare (physicians, dentists,
hospitals and health insurance funds) in Germany. The
manufacturer may request an advice meeting with the G-BA
in order to determine the appropriate comparative therapy
(ACT) and address any other relevant questions. Within
3 months of submission, the dossier is evaluated in most
cases by the Institute for Quality and Efficiency in Health
Care (IQWiG) [2]. The IQWiG evaluation results in a rec-
ommendation regarding the additional patient-relevant
benefit of the investigated drug. Three months after IQ-
WiG’s recommendation, the G-BA concludes the benefit
assessment by making a final decision regarding the addi-
tional benefit. The G-BA decision is based on the manu-
facturers’ dossier, IQWiG evaluation, as well as the results
of a public hearing. After the G-BA decision, price nego-
tiations between the SHI and the manufacturer begin. The
price negotiations must be finalised within 6 months. If no
agreement is reached in this time, an arbitration board is
called, which must reach a final pricing decision within
3 months.
Various key elements may be discriminated within the
AMNOG process [1, 3]. An ACT is used to determine the
additional benefit of the new medication. The ACT should
be identified based on the standards of evidence-based
medicine, the contents of the marketing authorisation,
recommendations in treatment guidelines, and other crite-
ria [1, 3]. The level of additional benefit versus the ACT is
categorised as: (1) major; (2) significant; (3) marginal; (4)
not quantifiable; (5) no; or (6) less.
The methodological basis of the benefit assessment and
uncertainties regarding outcome and study results are
covered in IQWiG’s publication on ‘General Methods’ [4].
Accordingly, the evidence base is grouped into the cate-
gories of ‘proof’, ‘indication’, or ‘hint’ based upon the
number and characteristics of studies provided, the cer-
tainty of results, and the observed effects (Table 1) [4].
Outcomes considered by IQWiG and G-BA in terms of
additional benefit are grouped into three dimensions:
mortality, morbidity and health-related quality of life
(HRQoL) [3, 4]. Fewer adverse events compared with the
ACT is considered an additional benefit of the new medi-
cine. All available information on adverse events has to be
included in the dossier [3, 4].
So far, only very few new products have passed through
the full AMNOG process, including price negotiations.
However, a considerable amount of experience has been
gathered regarding the early part of the process, i.e. the
early benefit assessment (EBA). The aim of our investi-
gation was to analyse the outcomes 18 month after intro-
ducing the new legislation and to identify critical areas that
require further discussion and development.
Fig. 1 Flow chart covering
benefit assessment and price
negotiation according to the
new German regulations since
January 2011
Table 1 Requirements for the assessment of level of evidence for an
additional benefit [4]
Conclusion Requirement
Number
of studies
Certainty
of results
Effect
Proof C2 Mostly high In the same direction
Indication C2 Mostly moderate In the same direction
1 High Statistically significant
Hint C2 Mostly low In the same direction
1 Moderate Statistically significant
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Methods
This analysis included all EBAs that commenced prior to 1
June 2012. The G-BA website (http://www.g-ba.de/
informationen/nutzenbewertung) was used to obtain the
manufacturers’ benefit dossiers, the IQWiG assessments,
and the G-BA decisions. The analysis specifically addres-
sed four areas of interest.
(1) Levels of additional benefit as stated by the IQWiG
and G-BA were compared. Positive (category 1–4:
major; significant; marginal; not quantifiable addi-
tional benefit) and negative (category 5–6: no/less
additional benefit) decisions were discriminated.
Subgroup analyses (‘slicing’) conducted by IQWiG
and G-BA were reviewed. Both total benefit scores
and subgroup scores were included in the analysis. To
compare total scores from IQWiG and G-BA, either
the total score (if provided) or the best available
subgroup score was used. Discrepancies between
IQWiG and G-BA decisions were identified and
analysed. Levels of evidence (proof, indication, hint)
reported by IQWiG and G-BA were compared.
(2) The ACT suggested by the G-BA was compared with
the ACT within the manufacturers’ dossier. Further-
more, phase III comparators were included, as derived
from the European Public Assessment Reports
(EPARs), which were downloaded from the website
of the European Medicines Agency (EMA) [5].
(3) Additional benefits were categorised according to the
three dimensions stated within the relevant social law,
i.e. §35 (1b) of the German Social Code Book V [6]:
mortality, morbidity, HRQoL. The manufacturers’
dossiers were reviewed regarding their respective
claims. Decisions by IQWiG and G-BA were ana-
lysed and compared regarding their acceptance of
those claims.
(4) Institute for Quality and Efficiency in Health Care
and G-BA decisions regarding adverse events, as well
as the weighting applied when deriving a total score,
were analysed.
Results
Thirty-one EBAs commenced prior to 1 June 2012 (Table 2).
The G-BA exempted ceftaroline fosamil, dexmedetomidine,
and piperaquine tetraphosphate/dihydroartemisinin from an
EBA [7] due to low expected costs for the SHI. Additionally,
the assessment of olmesartan medoxomil/amlodipine/
hydrochlorothiazide was discontinued by the G-BA [7].
Therefore, these four products were not included in this
analysis, resulting in inclusion of 27 EBAs.
For four new drugs (azilsartan medoxomil, bromfenac,
pitavastatin, regadenoson), the manufacturers did not submit
a dossier, leading to a no additional benefit decision by the
G-BA without an IQWiG evaluation [7]. For orphan drugs,
market authorisation is considered proof of additional benefit
by German regulations [§35a (1) German Social Code Book
V], but only up to an annual revenue of 50 million Euros.
Once this sales threshold is exceeded, orphan drugs are
assessed as conventional drugs [6]. Therefore, pirfenidone
and tafamidis meglumine were only investigated in terms of
their level of additional benefit, and not for the level of proof.
Additional benefit
Table 3 summarises the recommendations by IQWiG and
the respective G-BA decisions, in terms of additional ben-
efit, for the 27 products considered here. IQWiG concluded
that there were significant and marginal additional benefits
in six and three EBAs, respectively, and a non-quantifiable
additional benefit was concluded in two assessments. Half
of the new medicines were rated as having no additional
benefit by IQWiG (Fig. 2) [7]. Overall, G-BA decisions
were more positive than the IQWiG recommendations, with
G-BA concluding that about two-thirds of products had an
additional benefit (Fig. 2) [7]. Important differences in the
overall additional benefit between IQWiG recommenda-
tions and G-BA decisions were found in several EBAs [7].
A hearing is established in between the time of recom-
mendation by IQWiG and the time of the final decision by
G-BA. The results of this hearing have an influence on the
G-BA decision and could be considered as a reason for
differences in the assessment of IQWiG and G-BA. How-
ever, the way the results of the hearing affect the final
G-BA decision still remains unclear, because the respective
G-BA subcommittee for drugs decides in closed meetings
and the relationship between hearings and G-BA decisions
is not easy to understand.
Belimumab
Institute for Quality and Efficiency in Health Care con-
cluded no additional benefit, whereas G-BA concluded
there was a significant additional benefit. The reason for
the discrepancy was that G-BA accepted evidence versus
the comparator used in the phase III trials while IQWiG
disagreed with the ACT due to lack of adaptation of steroid
dose within those trials.
Cabazitaxel
Institute for Quality and Efficiency in Health Care sug-
gested a major additional benefit in terms of efficacy.
However, because of the reported adverse events, they
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recommended a total score of significant additional benefit.
G-BA also reduced the total additional benefit score by one
level due to the side-effect profile. However, G-BA did not
agree with IQWiG regarding the additional efficacy benefit
and decided for a significant additional benefit in terms of
efficacy and a total score of marginal additional benefit.
Table 2 New medicines in the EBA process
Drug Brand name Indication Manufacturer Start date
EBA
Abiraterone acetate Zytiga Prostate cancer Janssen-Cilag 01.10.2011
Aliskiren/amlodipine Rasilamlo Hypertension Novartis 15.05.2011
Apixaban Eliquis Prophylaxis of venous thromboembolism after
athroplasty (hip or knee replacement)
Bristol-Myers
Squibb
15.06.2011
Azilsartan medoxomil Edarbi Hypertension Takeda 15.01.2012
Belatacept Nulojix Graft rejection
Kidney transplantation
Bristol-Myers
Squibb
15.07.2011
Belimumab Benlysta Systemic lupus erythematosus GlaxoSmithKline 27.07.2011
Boceprevir Victrelis Chronic hepatitis C MSD Sharp &
Dohme
01.09.2011
Bromfenac Yellox Inflammation in the eye following operation to
remove cataract
Bausch und Lomb/
Dr. Mann
01.08.2011
Cabazitaxel Jevtana Prostate cancer Sanofi-Aventis 15.04.2011
Ceftaroline fosamil Zinforo Skin and soft-tissue infections, community-acquired
pneumonia
AstraZeneca 14.03.2012
Dexmedetomidine Dexdor Conscious sedation Orion 13.07.2011
Emtricitabine/rilpivirine/tenofovir
disoproxil
Eviplera HIV infection Gilead 15.01.2012
Eribulin Halaven Breast cancer Eisai 01.05.2011
Extract of Cannabis sativa Sativex Spasticity in multiple sclerosis Almirall Hermal 01.07.2011
Fampridine Fampyra Multiple sclerosis Biogen Idec 29.07.2011
Fingolimod Gilenya Multiple sclerosis Novartis 15.04.2011
Ipilimumab Yervoy Melanoma Bristol-Myers
Squibb
01.08.2011
Linagliptin Trajenta Diabetes mellitus type II Boehringer
Ingelheim
01.10.2011a
Microbial collagenase Xiapex Dupuytren’s contracture Pfizer 01.05.2011
Olmesartan medoxomil/amlodipine/
hydrochlorothiazide
Sevikar
HCT
Hypertension Daiichi Sankyo No status
Piperaquine tetraphosphate/
dihydroartemisinin
Eurartesim Malaria Sigma-tau
Arzneimittel
21.03.2012
Pirfenidone Esbriet Idiopathic pulmonary fibrosis InterMune 15.09.2011
Pitavastatin Livazo Primary hypercholesterolemia and mixed
dyslipidemia
Merckle Recordati 01.06.2011
Regadenoson Rapiscan Myocardial perfusion record Rapidscan Pharma
Solutions
15.04.2011
Retigabine Trobalt Epilepsy (add-on) GlaxoSmithKline 15.05.2011
Rilpivirine Edurant HIV infection Janssen-Cilag 15.01.2012
Tafamidis meglumine Vyndaqel Amyloidosis Pfizer 15.12.2011
Telaprevir Incivo Hepatitis C Janssen-Cilag 15.10.2011
Ticagrelor Brilique Acute coronary syndrome AstraZeneca 01.01.2011
Vandetanib Caprelsa Thyroid neoplasms AstraZeneca 15.03.2012
Vemurafenib Zelboraf Melanoma Roche 15.03.2012
a Re-assessment according to §35a (5b) German Social Code Book V had started on 01.09.2012
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Emtricitabine/rilpivirine/tenofovir disoproxil
Institute for Quality and Efficiency in Health Care con-
cluded there was no additional benefit. During the hearing
process, the manufacturer submitted further clinical data.
After evaluation of the new data G-BA concluded there
was a marginal additional benefit. For rilpivirine mono-
therapy, IQWiG suggested a major additional benefit,
whereas G-BA concluded a marginal additional benefit.
Eribulin
Institute for Quality and Efficiency in Health Care con-
cluded there was no additional benefit in both patient
populations, whereas G-BA concluded there was a mar-
ginal additional benefit in patients that cannot be re-
exposed to anthracycline and/or taxane treatment and less
benefit in patients that can be re-exposed to those treat-
ments. The key reason for the discrepancy was different
weighting of damage potential within the two subgroups
between IQWiG and G-BA.
Extract of Cannabis sativa
Institute for Quality and Efficiency in Health Care sug-
gested no additional benefit, whereas G-BA concluded a
marginal additional benefit. While IQWiG suggested that
the manufacturer did not match the suggested ACT, G-BA
accepted the data provided by the manufacturer.
Study populations were divided into subgroups more
frequently by IQWiG than by the manufacturers. In some
cases G-BA disregarded the patient subgroups recom-
mended by IQWiG and analysed different patient popula-
tions instead [7]. Importantly, the ACT defined by G-BA
may vary for different subgroups.
Fig. 2 Presence of additional
benefit as reported by IQWiG,
G-BA and HAS according to the
number of products evaluated
(n)
Table 3 Comparison of IQWiG assessment and G-BA decision for
new medicines regarding presence of additional benefit
IQWiG G-BA
Abiraterone acetate ? ?
Aliskiren/amlodipine - -
Apixaban ? ?
Azilsartan medoxomil n.d. -
Belatacept ? ?
Belimumab - ?
Boceprevir ? ?
Bromfenac n.d. -
Cabazitaxel ? ?
Emtricitabine/rilpivirine/tenofovir disoproxil - ?
Eribulin - ?
Extract of Cannabis sativa - ?
Fampridine - -
Fingolimod ? ?
Ipilimumab ? ?
Linagliptin - -
Microbial collagenase - -
Pirfenidone - ?
Pitavastatin n.d. -
Regadenoson n.d. -
Retigabine - -
Rilpivirine ? ?
Tafamidis meglumine n.d. ?
Telaprevir ? ?
Ticagrelor ? ?
Vandetanib - -
Vemurafenib ? ?
In case of different subgroups within an EBA, the best subgroup
assessment was used
Information on http://www.g-ba.de/informationen/nutzenbewertung/
in manufacturers’ dossier and G-BA decision
?, additional benefit; -, no additional benefit; n.d., not determined
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In five assessments, comparative data versus ACT were
missing for defined subgroups. IQWiG and G-BA were not
able to identify any additional benefit for certain sub-
groups, i.e. in the EBAs for abiraterone acetate, cabazit-
axel, fingolimod, microbial collagenase and ticagrelor [7].
For eribulin, only some of the data presented by the
manufacturer were deemed relevant by IQWiG and G-BA
for the specified subgroups, leading to a decrease in the
level of evidence for additional benefit [7]. Omission of
data for relevant populations led to the dossier for vande-
tanib being deemed unacceptable for benefit assessment by
IQWiG and G-BA [7]. Similarly, IQWiG considered the
dossier of emtricitabine/rilpivirine/tenofovir disoproxil as
incomplete due to missing investigations regarding sub-
group differences [7].
In six benefit decisions by G-BA a time limit was
imposed.
Appropriate comparative therapy (ACT)
Table 4 summarises comparators used in phase III clinical
trials, the ACT used in the manufacturers’ dossiers, and the
Table 4 Comparison of ACT used by manufacturer in the EBA dossiers, ACT defined by G-BA, and comparators used in phase III trials
Phase III comparator [5] ACT in manufacturers’
dossiera,b
ACT defined by G-BAa,b
ACT recommendation by G-BA different from Phase III comparator but accepted by manufacturer
Fampridine Placebo (add-on immunomodulatory
therapy)
Physiotherapy Physiotherapy according to German remedies
regulations; OST for multiple sclerosis
Abiraterone
acetatec
Placebo (add-on to prednisone or
prednisolone)
II: Docetaxel II: Docetaxel (add-on to prednisone, prednisolone)
Fingolimodd a) Placebo
b) b-Interferon
I: Glatiramer acetate I: Glatiramer acetate
Vandetanib Placebo BSC BSC
ACT recommendation by G-BA not accepted by manufacturer
Microbial
collagenasee
Placebo Partial fasciectomy
(PF)
I: No therapy
II: Percutaneous needle fasciotomy (PNF)
III: PF
IV: PNF
Ticagrelorf Clopidogrel ? ASA Clopidogrel ? ASA III: Prasugrel ? ASA
IV: Monotherapy with ASA
Cabazitaxel Mitoxantrone (add-on to prednisone and
prednisolone)
Mitoxantrone (add-on
to prednisone and
prednisolone)
I (BSC): Dexamethasone, prednisone, prednisolone
or methylprednisolone ? BSC
Pirfenidone Placebo Not determined BSC
Aliskiren/
amlodipine
Aliskiren and amlodipine alone Aliskiren and
amlodipine alone
Combination of ACE-inhibitor (lisinoprile or
ramiprile or enalaprile) and calcium-antagonist
(amlodipine or nitrendipine)
Linaglipting Placebo alone or add on to metformin, a
combination of metformin plus
sulphonylurea or pioglitazone
Sitagliptin I: Sulphonylurea (glibenclamide, glimepiride)
II: Sulphonylurea (glibenclamide,
glimepiride) ? metformin
III: Metformin ? human insuline
Retigabine Placebo Lacosamide Lamotrigine or topiramate
ASA acetylsalicylic acid, BSC best supportive care, OST optimised standard treatment
a Information on http://www.g-ba.de/informationen/nutzenbewertung/ in manufacturer’s dossier and G-BA decision
b ACT can differ among subgroups. Subgroups are marked with Roman numerals
c Patients, where re-exposure with Docetaxel is possible
d Relapsing-remitting multiple sclerosis (RRMS), non-responder to completed b-interferon therapy
e Subgroup classification according to disease severity (Tubiana stage)
f Subgroup classification according to indication (III: ST-elevation myocardial infarction (STEMI) managed with percutaneous coronary
intervention (PCI); IV: STEMI managed with coronary artery bypass grafting (CABG)
g Subgroup classification according to use of mono- (I), dual (II) or triple (III) therapy with linagliptin
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ACT as proposed by G-BA for products, where discrep-
ancies exist.
The manufacturer used the ACT suggested by G-BA in
16 of 23 benefit dossiers (Fig. 3) [7]. The assessments of
azilsartan medoxomil, bromfenac, pitavastatin and regad-
enoson were excluded from this analysis due to missing
dossiers. In three of the 16 cases (abiraterone acetate,
fampridine and fingolimod), data for the suggested com-
parators (e.g. for subgroups) were not available from phase
III clinical trials or were not reported in the dossier
(Table 4). For the remaining seven EBAs, the manufac-
turer did not follow the G-BA recommendations and
developed dossiers based on a different ACT for all
patients (cabazitaxel, aliskiren/amlodipine, linagliptin,
pirfenidone and retigabine) or for specific subgroups
(microbial collagenase and ticagrelor) (Table 4; Fig. 3) [7].
The ACT suggested by G-BA differed in 12 assessments
from the comparator used in phase III clinical studies.
Disagreement regarding the ACT was one of the major
reasons for a no additional benefit conclusion by G-BA,
either for the EBA as a whole or for specific subgroups
within the dossier.
Due to missing data on the suggested comparator, G-BA
decided that there was no additional benefit in certain
subgroups in five of the assessments (abiraterone acetate,
cabazitaxel, ticagrelor, fingolimod and microbial collage-
nase) (Table 4). Disagreement between the manufacturer
and G-BA regarding the ACT was found in four EBAs
(aliskiren/amlodipine, linagliptin, pirfenidone and retiga-
bine) (Table 4) [7].
G-BA defined an individual optimised standard therapy
(OST) as ACT in nine EBAs, and best supportive care
(BSC) was suggested as an appropriate comparator in five
assessments. Although both the manufacturer and G-BA
used OST as ACT in the EBA of belimumab, the definition
of OST differed between the manufacturer, IQWiG and
G-BA. Whereas the studies presented by the manufacturer
were not accepted by IQWiG, G-BA decided to accept
inclusion of the studies and concluded a significant addi-
tional benefit for belimumab [7]. Similarly, the interpre-
tation of OST differed between IQWiG and G-BA for the
extract of Cannabis sativa [7].
In the EBA of fampridine, physiotherapy was used as
ACT. The manufacturer’s dossier showed methodological
deficits due to inadequate documentation of physiotherapy
and medical interventions to the level specified by G-BA.
Additionally, the study population that was used for indi-
rect comparison included patients with lower degrees of
disability than the values required for treatment with
fampridine. Therefore, IQWiG and G-BA concluded that
the evidence for an additional benefit was not adequate [7].
Direct comparisons between investigated drugs and
ACTs are favoured by IQWiG and G-BA [4, 8]. In six of
the 12 cases where the comparator used in the phase III
trials differed from the ACT recommended by G-BA, the
manufacturer included an indirect comparison of data from
two separate trials in the dossier. Minor acceptance of these
indirect comparisons by IQWiG and G-BA was evident in
the evaluation of abiraterone acetate, fampridine and
microbial collagenase. The indirect comparison for ti-
cagrelor based on the major PLATO and TRITON studies
was successful [7].
Patient-relevant endpoints and benefit domains
Table 5 summarises the manufacturers’ conclusions, the
IQWiG assessment, and the G-BA decisions regarding
patient-relevant outcomes. Data presented by the manu-
facturer for mortality, morbidity and HRQoL were accepted
for evaluation by IQWiG and G-BA in 11, 14 and 10 EBAs,
respectively. An additional benefit in at least one endpoint
was confirmed in 14 EBAs by IQWiG and/or G-BA.
Fig. 3 Acceptance of ACT
selected by G-BA and
consequences on the added
benefit decision
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In six EBAs, an additional benefit on mortality was
confirmed by IQWiG and G-BA. All but one of the
oncology submissions (vandetanib) were able to demon-
strate survival benefit [7]. In the dossiers for abiraterone
acetate, cabazitaxel, eribulin, ipilimumab and vemurafenib,
an additional benefit in overall survival was reported [7].
Furthermore, ticagrelor showed both an additional overall
and cardiovascular mortality benefit [7].
An additional benefit on morbidity was reported in
seven IQWiG evaluations. G-BA agreed with these seven
decisions and, in addition, concluded that belatacept, bel-
imumab and the extract of Cannabis sativa had additional
benefits on morbidity [7].
No significant differences between any of the investi-
gated drugs and the ACT regarding HRQoL were evident
and therefore no proof for additional benefit was recogni-
sed by IQWiG and G-BA for this dimension [7].
Discrepancies were observed in the interpretation of the
value of surrogate endpoints reported in the EBAs of belata-
cept, boceprevir, telaprevir and HIV products [7]. The manu-
facturer of belatacept reported the glomerular filtration rate
(GFR) as a surrogate endpoint for graft function; however,
IQWiG did not consider GFR to be a patient-relevant endpoint,
stating that it needs further validation in order to be accepted.
G-BA agreed with the manufacturer and acknowledged GFR
as a relevant endpoint. In hepatitis C, sustained virological
response (SVR) was considered by IQWiG as a valid surrogate
endpoint only for hepatocellular carcinoma. Nevertheless,
G-BA accepted SVR as an overall patient-relevant endpoint in
the decisions for boceprevir and telaprevir [7].
Table 5 Additional benefits
claimed by the manufacturer
compared with those considered
as addressed by IQWiG and
G-BA
DVT deep vein thrombosis
? Additional benefit confirmed;
± No significant differences
observed, no additional benefit;
-Less benefit
a Information on
http://www.g-ba.de/
informationen/
nutzenbewertung/ in manufac-
turers’ dossier and G-BA
decision
b In case of different subgroups
within an EBA, the most
positive assessment is stated
Manufacturera,b IQWiG/G-BAa,b
Mortality Morbidity HRQoL Mortality Morbidity HRQoL
Abiraterone acetate ? ? ? ? ?
Aliskiren/amlodipine ? ?
Apixaban ± Embolism: ±
DVT: ?
± Embolism:
Knee: –
Hip: ±
DVT: ?
Belatacept ± ? ± ± IQWiG:
±
G-BA: ?
±
Belimumab ? ? G-BA: ? G-BA: ±
Boceprevir ? ± ?
Cabazitaxel ? ? ± ? ±
Emtricitabine/rilpivirine/
tenofovir disoproxil
± ± ?
Eribulin ? ?
Extract of Cannabis sativa ? ? G-BA: ? G-BA: ±
Fampridine ?
Fingolimod ? ± ± ±
Ipilimumab ? ± ± ? ±
Linagliptin ±
Microbial collagenase ?
Pirfenidone ± ? ± ± ± ±
Retigabine ±
Rilpivirine ? ± IQWiG: ?
G-BA: ±
±
Tafamidis meglumine ? ? ± ? ±
Telaprevir ? ? ? ±
Ticagrelor ? ? ? ?
Vandetanib ? ±
Vemurafenib ? ± ± ? ± ±
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Assessment and weighting of adverse events
The EBA dossier submissions have to include all relevant
safety data. Reduction of adverse events in comparison
with the ACT is considered an additional benefit of a new
medicine. Figure 4 shows the G-BA’s view on the adverse
events of the new drugs. In seven EBAs, there was evi-
dence of an increased number or greater severity of adverse
events, thus causing a greater negative outcome on the
patient compared with the ACT. Improvement in adverse
events compared with the ACT was found in four EBAs.
G-BA concluded that there was no proof or indication for
additional harm of the new medicine in comparison with
the ACT in five EBAs.
In seven EBAs (boceprevir, cabazitaxel, eribulin, ipi-
limumab, telaprevir, ticagrelor and vemurafenib), positive
effects on patient-relevant endpoints and negative effects
from side effects were considered by IQWiG to balance
each other out. However, only in the cases of cabazitaxel
and eribulin did G-BA follow IQWiG’s recommendation
and reduce the total benefit score due to adverse events (in
addition, G-BA did not agree with IQWiG on the effec-
tiveness of cabazitaxel) [7] (Fig. 4).
The positive side-effect profile of emtricitabine/rilpi-
virine/tenofovir disoproxil, i.e. fewer dermatological and
neurological adverse events, led to an upgrading of the
overall benefit score by G-BA [7]. The additional benefit of
rilpivirine was based entirely on the reduction of neuro-
logical adverse events [7]. Flu-like symptoms were
improved by fingolimod, resulting in an elevated benefit
score [7] (Fig. 4).
The conclusions of IQWiG and G-BA on adverse events
were sometimes related to subgroup analyses (belatacept,
boceprevir, fingolimod and telaprevir) [7]. In some cases,
data for the relevant subgroup were considered as missing
in the manufacturers’ dossier (eribulin and ticagrelor) [7].
Eribulin is the only drug so far to receive a score of less
benefit by G-BA in a subgroup of patients. G-BA decided
that in patients who can be re-exposed to treatment with
taxane/anthracycline, eribulin has no additional benefit in
terms of efficacy and the potential for additional harm,
leading to a total score of less benefit in that subgroup [7].
Discussion
In a recent report of the 22 new pharmaceutical products
licensed in Germany in 2011, 46 % were considered to
represent a significant innovation in terms of having a
novel mechanism of action and targeting a new indication
[9]. An additional 36 % of the products were considered to
be partially innovative in that they provided a clinical
benefit in a given indication. For 18 % of the new drugs, no
real innovation could be observed (so-called me-too
products) [9]. Similarly, it has been reported that around
25 % of new medicines authorised in Europe between 1995
and 2010 showed an important degree of therapeutic
innovation [10–12]. The definition of an innovative medi-
cine according to AMNOG includes additional benefit for
patients in comparison with existing treatments. In a recent
press release, G-BA announced that in 64 % of evaluations
an additional benefit was reported [13]. Our analysis
showed similar results. Out of 27 evaluations, 17 (63 %)
concluded an additional benefit (Table 3). This is also in
line with health technology assessments (HTA) of health
authorities in other countries, such as the French Haute
Autorite´ de Sante´ (HAS).
In France, the transparency committee, as part of the
National Authority for Health (HAS), provides guidance on
the positive listing of drugs, taking into account their
comparative value and their role for the target disease. Two
levels of benefit are used for each drug: the level of benefit
rendered by the medicine to the patient, expressed as
‘Service Me´dical Rendu’ (SMR), and the level of addi-
tional benefit that the new drug is expected to provide
compared with alternatives, expressed as ‘Amelioration du
Fig. 4 Evaluation of negative patient-relevant outcomes by G-BA in
the included EBAs. For products at the end of the arrows this
evaluation leads to an up- and downgrade, respectively. This
evaluation does not influence the benefit level of the products before
the gap
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Service Me´dical Rendu’ (ASMR) in five categories from
ASMR I (major improvement) to ASMR V (no improve-
ment) [14]. The SMR determines inclusion in a positive list
and the respective reimbursement rate fixed by the Asso-
ciation of Health Insurance Funds (UNCAM). Drugs with
insufficient SMR are not recommended for reimbursement.
The ASMR is taken into account when setting a price for
the drug as the final outcome of the negotiations between
the manufacturer and the Committee for the Pricing of
Healthcare Products (CEPS).
The HAS has evaluated 22 of the 27 medicines included
in our review [15]. Both the HAS and G-BA reported no
additional benefit for five of these 22 common products at
the same time (bromfenac, fampridine, linagliptin, micro-
bial collagenase, retigabine). In 16 of 22 decisions, the
agreement between the assessments in Germany and
France was either moderate or strong (Table 6). In three
cases there was a definite disagreement, whereas in one of
the two health systems no additional benefit at all was
assigned (combination of emtricitabine/rilpivirine/tenofo-
vir, rilpivirine, vandetanib). This applies to both Germany
and France. For example, in the case of vandetanib, an
ASMR IV was assigned in France whereas in Germany,
G-BA decided that there is no additional benefit. For
Table 6 Comparison of the assessment of common new drugs in Germany and France
Drug G-BA assessmenta HAS assessmentb (Sub) populationc Agreement
Abiraterone acetate Ind. significant (II) Moderate ASMR III G-BA: BSC patients ?
Apixaban Ind. marginal (III) Minor ASMR IV G-BA: HIP operation ? ?
Belatacept Ind. marginal (III) Minor ASMR IV HAS: young, EB-virus ??
Belimumab Ind. significant (II) Minor ASMR IV -
Boceprevir Ind. not quant. (IV) Moderate ASMR III HAS: ther.-experienced ?
Bromfenac No (V)d No improv ASMR V ? ?
Cabazitaxel Ind. marginal (III) Minor ASMR IV HAS: 2nd line after Dtxe
G-BA: no Dtx re-therapy
??
Emtricitabine/rilpivirine/tenofovir Proof marginal (III) No improv ASMR V - -
Eribulin Hint marginal (III) Minor ASMR IV ? ?
Fampridine No (V) No improv ASMR V ? ?
Fingolimod Hint marginal (III) Minor ASMR IV G-BA: RRMS patients ??
Ipilimumab Ind. significant (II) Minor ASMR IV -
Linagliptin* No (V)d,f,g No improv ASMR V HAS: combin. therapy ? ?
Microbial collagenase No (V)g No SMRh (?)
Pirfenidone Not quant (IV)i Minor ASMR IV ?
Retigabine No (V)d,g No improv ASMR V HAS: 2line ?
Rilpivirine Proof marginal (III) No improv ASMR V - -
Tafamidis meglumine Marginal (III)i Minor ASMR IV ? ?
Telaprevir Ind. not quant (IV) Moderate ASMR III HAS: ther.-experienced ?
Ticagrelor Proof signific. (II) Minor ASMR IV G-BA: UA/NSTEMI -
Vandetanib No (V)d Minor ASMR IV - -
Vemurafenib Ind. Significant (II) Moderate ASMR III ?
?/??/- /--: moderate agreement/strong agreement/at least two classes difference/different direction of (additional) benefit
* Linagliptin has been compared in Germany versus sulfonylurea, in France versus sitagliptin. G-BA is now reassessing linagliptin
a According to the German classification scheme: major (I), significant (II), marginal (III), not quantifiable (IV), no additional benefit (V) and
less benefit with proof, indication and hint as conclusion categories
b According to the French classification system for additional benefit ‘Amelioration du Service Me´dical Rendu’ (ASMR) of the Haute Autorite´
de Sante´ (HAS): ASMR I major, ASMR II important, ASMR III moderate, ASMR IV minor and ASMR V no improvement
c In case of more subpopulations the comparison is referring to the respective subpopulation with the highest additional benefit classification
d No benefit assessment dossier was submitted or no additional benefit was assigned due to formal reasons (e.g. inappropriate comparator)
e Docetaxel including chemotherapy
f Re-assessment according to §35a (5b) German Social Code Book V has started on 01.09.2012
g Opt-out in Germany
h ‘Service Me´dical Rendu’ is referring only to the benefit, not to the additional benefit
i Orphan drug
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rilpivirine monotherapy or triple-combination the opposite
occurred (Table 6). Comparison with NICE was not con-
ducted due to methodological differences between the two
HTA approaches.
In addition, some further aspects have to be taken into
account when interpreting the results. G-BA often ‘sliced’
the total patient population into subgroups and assigned
different additional benefit scores for the identified sub-
groups. Of the total number of 40 subgroups, an additional
benefit was reported in only about 50 % (Fig. 5). The
number of patients studied in each of the subgroups can be
calculated from the manufacturers’ dossiers; only 40 % of
the patients were in subgroups in which the new drug had
an additional benefit according to the G-BA (Fig. 6).
Whereas IQWiG uses a threshold concept to define the
impact that leads to a major, significant or marginal addi-
tional benefit [16], G-BA did not use this concept for its
decisions. It should be mentioned that G-BA has not
assigned the category of major additional benefit to any
single drug evaluated so far, and it is therefore unclear
what impact a drug would need to have in order for G-BA
to consider it as having a major additional benefit. The
pivotal trial of vemurafenib, which is indicated for the
treatment of melanoma, was terminated early at the request
of the regulatory bodies due to the observed improvement
in overall survival benefit. In contrast to the manufacturer,
the G-BA did not consider that the statement by the reg-
ulatory bodies should be interpreted as proof of a major
additional benefit [17].
This analysis indicates disagreement between the ACTs
suggested by G-BA and the manufacturers (Table 4). Ten
of 23 EBAs (44 %) showed only limited agreement (6
EBAs) or disagreement (4 EBAs) in the selection of ACT.
Three manufacturers applied the comparator that had been
suggested by G-BA even though relevant data were not
available. As a consequence, these three products received
negative G-BA decisions due to the lack of data.
Until now, the advice meetings of the manufacturers
with G-BA have taken place at a late stage in the clinical
development process, after initiation of phase III studies;
therefore the design of the phase III studies could not take
into account the feedback and requests of G-BA. The most
recent legislation requires the involvement of the health
authorities during early advice meetings (before initiation
of phase III clinical trials) between the pharmaceutical
manufacturer and G-BA. It is hoped that discrepancies
concerning the comparators used for phase III clinical
studies and benefit assessments, as well as discrepancies
regarding the selection of patient-relevant endpoints, will
diminish over time as a result of this initiative.
Many of the ACTs suggested by G-BA lack appropriate
clinical evidence. When applying the IQWiG hierarchy of
evidence, many of the suggested ACTs would not even
qualify for a hint, rendering the comparison of the innova-
tive treatment with the ACT somewhat arbitrary. The most
frequently applied ACT was best supportive care (BSC).
However, the definition of BSC varied considerably. For
example, physiotherapy was selected as the comparator for
the multiple sclerosis drug fampridine [7] despite a lack of
evidence from clinical trials that physiotherapy offers a
statistically significant benefit. In the assessment of cabaz-
itaxel for the treatment of prostate cancer, the manufacturer
used mitoxantrone as ACT, because it is used (with or
without prednisone/prednisolone) in over 50 % of patients
in Germany. In contrast, G-BA selected dexamethasone,
prednisone, prednisolone or methylprednisolone, in addi-
tion to BSC as the ACT, and considered mitoxantrone to be
part of BSC [7]. Similarly, percutaneous needle fasciotomy
was chosen by G-BA as the ACT for microbial collagenase
in two subgroups within the dossier [7], even though per-
cutaneous needle fasciotomy (PNF) is used in less than
10 % of cases in general practice in Germany and there are
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Fig. 5 Level of additional benefit (%) in 40 assessed patient
subgroups in the 23 evaluated EBAs (23 of 31 drugs, 4 drugs
exempted and 4 without submitted dossier)
0
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Fig. 6 Level of additional benefit compared to % and total number of
patients in 39 (Rilpivirine and Emtricitabine/Rilpivirine/Tenofovir
disoproxil are referring to the same population) assessed patient
subgroups in the 23 (23 from 31 drugs, 4 exempted drugs and 4 drugs
without submitted dossier) evaluated EBAs. Total (sum of mean
values from G-BA decisions: 1,408,742 patients) (Without the
Linagliptin population of 1,219,500 patients due to the dossier re-
submission)
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no randomised clinical trial (RCT) data regarding PNF’s
effect on patient-relevant outcomes.
There is also some debate over which endpoints should be
considered to be relevant for patients. The endpoints in
clinical trials differ across disease areas. For example, in
oncology there is a focus on survival benefit and measures of
disease morbidity, such as progression-free or disease-free
survival, while in virology, endpoints primarily address viral
load and in rheumatology, clinical composite scores are the
current standard. While these endpoints have become
established and recognised by the regulatory bodies, they are
not necessarily accepted by HTA bodies. For example, PFS
was not considered a relevant endpoint in the assessment of
various oncology drugs (e.g. abiraterone acetate, cabazitaxel
and vemurafenib) and SVR was not considered relevant by
IQWiG in the assessment of boceprevir and telaprevir for the
treatment of hepatitis C. However, such endpoints may be
very valuable in detecting changes in morbidity before they
become symptomatic for patients (i.e. before functional
deficits occur). Furthermore, progression of cancer usually
requires a change in therapy and is often associated with
anxiety for patients, suggesting that PFS should be consid-
ered a patient-relevant endpoint. Similarly, SVR is a marker
of hepatitis C progression that may detect changes in disease
severity, even before they become symptomatic. Although
IQWiG considered SVR irrelevant, G-BA decided to accept
SVR as a patient-relevant endpoint, demonstrating incon-
sistency in the interpretation for patient relevance.
The German Social Law discriminates three dimensions
of patient-relevant endpoints: mortality, morbidity and
HRQoL [6]. However, established disease-specific end-
points in clinical trials do not address the impact on all three
dimensions [18]. In particular, none of the additional benefits
granted by the G-BA were based on HRQoL, which indicates
major methodological challenges with the reliable assess-
ment of HRQoL within clinical development programmes.
As described in the EMA benefit-risk programme [19],
regulatory bodies put enormous emphasis on the appropriate
classification of adverse events and on the balancing of risks
and benefits. As the impact on adverse events is a key
component of the G-BA decisions on overall additional
benefit, some issues require further clarification. The basis
of the EMA grading of adverse events is the Common Ter-
minology Criteria for Adverse Events (CTCAE) classifica-
tion [20]. Within CTCAE investigations, symptomatic
myocardial infarction, pure abnormalities of cardiac
enzymes, and a decrease in white blood cells to\1,000 mm3
qualify as grade 4 adverse events. It may be assumed that
G-BA would not consider a transient decrease in white blood
cell count as patient relevant, whereas it would consider a
symptomatic myocardial infarction to be patient relevant. A
systematic approach to classify the severity of patient-rele-
vant adverse events is therefore required. The G-BA has to
further define and clarify its categorisation of adverse events
[12] beyond the definition used by the EMA.
The evidence hierarchy within the AMNOG process
considers RCTs as the gold standard for evidence devel-
opment [8]. It should be noted, however, that clinical trials
are usually powered for efficacy but not for adverse events.
Therefore, alternative methods of evidence generation have
to be developed and applied that take into account clinical
aspects, such as manageability and reversibility of adverse
events.
Balancing benefit and risk is a key feature of the EMA
review process. Granting marketing authorisation to a drug
implies a positive benefit-risk balance. In contrast, a G-BA
decision of less benefit (as occurred in one of the subgroups
in the assessment of eribulin) implies a negative benefit-
risk balance. An alignment of regulatory and G-BA
approaches therefore seems critical to provide patients with
a clear understanding of the benefit-risk ratio.
Almost 2 years after introduction of the AMNOG legis-
lation, only very limited information is available regarding
the full AMNOG process, e.g. details of price negotiation are
lacking in the public domain. Nevertheless, a considerable
amount of experience has been gained in the EBA proce-
dures. There is significant variability in the additional benefit
reported between pharmaceutical manufacturers, IQWiG
and G-BA, and this becomes apparent in four key areas: ACT
selection, subgroup definition, definition of patient-relevant
endpoints (mortality, morbidity and HRQoL), and the impact
of selected adverse events on benefit assessment. It also
remains unclear under what circumstances a manufacturer
may deviate from the assessment methodologies of IQWiG
and G-BA, and to what extent benefit assessment will be
penalised for such deviations. The hope remains, however,
that increased experience [21] and earlier interaction
between manufacturers, regulatory authorities, and HTA
authorities, may encourage more streamlined and integrated
regulatory and HTA programmes.
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